Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.34

€4.34

-1.140%
-0.05
-1.140%
-
 
15.12.25 / Frankfurt WKN: A2QCWK / Name: Nyxoah S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Nyxoah S.a. Stock

A loss of -1.140% shows a downward development for Nyxoah S.a..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Nyxoah S.a. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Nyxoah S.a. in the next few years

Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
EQS-News: Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
EQS-News: Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
EQS-News: Nyxoah Reports Second Quarter Financial and Operating Results
EQS-News: Nyxoah Reports Second Quarter Financial and Operating Results
EQS-News: Nyxoah Reports Second Quarter Financial and Operating Results
EQS-News: Nyxoah Announces Preliminary Results for the Second Quarter of 2025
EQS-News: Nyxoah Announces Preliminary Results for the Second Quarter of 2025
EQS-News: Nyxoah Announces Preliminary Results for the Second Quarter of 2025